Objective: Our recent study for the first time reported genotyping method of the diazepam binding inhibitor (DBI) rs2276596 polymorphism using a Polymerase Chain Reaction-Restriction Fragment Length Polymor- phism (PCR-RFLP), and revealed a significant relationships between this polymorphism and alcohol depend- ence. In this study, to facilitate elucidation of the pathogeneses of psychoses including schizophrenia and mood (affective) disorders, we investigated the relationship between the DBI rs2276596 polymorphism (C/A) and psychoses.
Method: We analyzed the DBI genotypes using the PCR-RFLP method in healthy controls, and psychotics including schizophrenia and mood (affective) disorders (including recurrent depressive disorder and bipolar affective disorder) (ICD-10: F31, F33).
Result: There was no significant difference in the rs2276596 genotype and allele frequencies of the DBI gene between these psychoses and healthy controls.
Conclusion: The present data suggested that a mutated allele of the DBI was not one of the risk factors for schizophrenia and mood (affective) disorders, as for the rs2276596 polymorphism. [Original].